Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06857942 · ClinicalTrials.gov registry record · Phase 4
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
A Phase 4 study of Psoriasis and Overweight or Obesity, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 200
- Enrollment target
- 20
- Study locations
NCT06857942 is a Phase 4 study of Psoriasis and Overweight or Obesity that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 200 participants, below the 487-participant average among 125 other Psoriasis trials with a reported enrollment target (59% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT06857942, a Phase 4 study of Psoriasis and Overweight or Obesity, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe plaque PsO and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.
Conditions Studied
Interventions
- DRUG Tirzepatide
Study Locations (20)
Florida
- Alliance for Multispecialty Research, LLC - Fort Myers
- NeoClinical Research - Hialeah
- Skin Care Research - Hollywood
- Encore Medical Research - Hollywood
- Palm Harbor Dermatology PA d/b/a TrueBlue Clinical Research - Tampa
- TruDerm & TruSpa - Wellington
California
- First OC Dermatology Research Inc - Fountain Valley
- Center For Dermatology Clinical Research, Inc. - Fremont
- Metropolis Dermatology - Los Angeles
- Northridge Clinical Trials - Northridge
Michigan
- David Fivenson, MD, PLC - Ann Arbor
- Great Lakes Research Group, Inc. - Bay City
- The Derm Institute of West Michigan - Caledonia
Indiana
- Dawes Fretzin Clinical Research Group, LLC - Indianapolis
- The Indiana Clinical Trials Center, PC - Plainfield
Arizona
- Medical Dermatology Specialists - Phoenix
Georgia
- Southeast Research Specialists - Douglasville
Kentucky
- Equity Medical - Bowling Green - Bowling Green
Maryland
- Dermatology and Skin Cancer Specialists, LLC - Rockville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-03-19 |
| Est. Completion | 2028-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06857942
The ClinicalTrials.gov registry entry for NCT06857942 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 487-participant average among 125 other Psoriasis trials with a reported enrollment target (59% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which Tirzepatide is the first listed.
NCT06857942 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, California, Michigan.
Frequently Asked Questions
What is clinical trial NCT06857942 about?
NCT06857942 is a clinical study titled "A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)". The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe plaque PsO and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.
What is the current status of trial NCT06857942?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2025-03-19. Estimated completion is 2028-05.
What conditions does trial NCT06857942 study?
This clinical trial studies the following conditions: Psoriasis, Overweight or Obesity.
What interventions are being tested in trial NCT06857942?
The interventions under investigation include: Tirzepatide (DRUG).
Who is sponsoring clinical trial NCT06857942?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06857942 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Duobrii in Combination With Biologics
RECRUITING · Phase 4
-
Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics
RECRUITING · Phase 4
-
ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.
RECRUITING · Phase 4
-
A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis
RECRUITING · Phase 4
-
Taltz in Combination With Enstilar for Psoriasis
RECRUITING · Phase 4
-
A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.